Kaleido Biosciences Inc (NASDAQ: KLDO) reported positive results from a non-IND study of KB109 in patients with mild-to-moderate COVID-19.

• KB109 demonstrated an overall favorable safety and tolerability profile with no unexpected treatment-related adverse events.

• The treatment reduced healthcare utilization, as measured by the total number of hospitalizations, emergency room visits, and urgent care visits by approximately 62% among patients with one or more comorbidity and about 51% overall.

• For patients with one or more comorbidity, KB109 reduced the median time to resolving the 13 overall COVID-19 symptoms from 30 to 21 days.

• The study also demonstrated a significant reduction in recovery time for patients aged 45 and older or with one or more comorbidity who received KB109 plus self-supportive care compared to patients receiving self-supportive care alone.

• KB109 is a novel, orally administered product candidate based on the Company's Microbiome Metabolic Therapy platform.

• Price Action: KLDO shares are up 8.86% at $10.81 in premarket trading on the last check Wednesday.

See more from Benzinga

• Click here for options trades from Benzinga

• Myovant/Pfizer's Relugolix Combo Therapy Shows Sustained Clinical Benefit In Uterine Fibroids

• ProQR Therapeutics Is Trading Higher On Positive QR-421a Data In Usher Syndrome

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.